» Articles » PMID: 29156762

Glutaminase Inhibition in Multiple Myeloma Induces Apoptosis MYC Degradation

Overview
Journal Oncotarget
Specialty Oncology
Date 2017 Nov 22
PMID 29156762
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Multiple Myeloma (MM) is an incurable hematological malignancy affecting millions of people worldwide. As in all tumor cells both glucose and more recently glutamine have been identified as important for MM cellular metabolism, however there is some dispute as to the role of glutamine in MM cell survival. Here we show that the small molecule inhibitor compound 968 effectively inhibits glutaminase and that this inhibition induces apoptosis in both human multiple myeloma cell lines (HMCLs) and primary patient material. The HMCL U266 which does not express MYC was insensitive to both glutamine removal and compound 968, but ectopic expression of MYC imparted sensitivity. Finally, we show that glutamine depletion is reflected by rapid loss of MYC protein which is independent of transcription and post translational modifications. However, MYC loss is dependent on proteasomal activity, and this loss was paralleled by an equally rapid induction of apoptosis. These findings are in contrast to those of glucose depletion which largely affected rates of proliferation in HMCLs, but had no effects on either MYC expression or viability. Therefore, inhibition of glutaminolysis is effective at inducing apoptosis and thus serves as a possible therapeutic target in MM.

Citing Articles

Inhibition of glutaminolysis alone and in combination with HDAC inhibitor has anti-myeloma therapeutic effects.

Okabe S, Tanaka Y, Moriyama M, Gotoh A Cancer Drug Resist. 2024; 7:25.

PMID: 39050886 PMC: 11267151. DOI: 10.20517/cdr.2024.35.


MYC dependency in GLS1 and NAMPT is a therapeutic vulnerability in multiple myeloma.

Hasan Bou Issa L, Flechon L, Laine W, Ouelkdite A, Gaggero S, Cozzani A iScience. 2024; 27(4):109417.

PMID: 38510131 PMC: 10952034. DOI: 10.1016/j.isci.2024.109417.


Shutting off the fuel supply to target metabolic vulnerabilities in multiple myeloma.

Rana P, Goparaju K, Driscoll J Front Oncol. 2023; 13:1141851.

PMID: 37361580 PMC: 10285382. DOI: 10.3389/fonc.2023.1141851.


Deregulated Metabolic Pathways in Ovarian Cancer: Cause and Consequence.

Murali R, Balasubramaniam V, Srinivas S, Sundaram S, Venkatraman G, Warrier S Metabolites. 2023; 13(4).

PMID: 37110218 PMC: 10141515. DOI: 10.3390/metabo13040560.


Metabolic changes underlying drug resistance in the multiple myeloma tumor microenvironment.

Matamala Montoya M, van Slobbe G, Chang J, Zaal E, Berkers C Front Oncol. 2023; 13:1155621.

PMID: 37091139 PMC: 10117897. DOI: 10.3389/fonc.2023.1155621.


References
1.
Dang C . Rethinking the Warburg effect with Myc micromanaging glutamine metabolism. Cancer Res. 2010; 70(3):859-62. PMC: 2818441. DOI: 10.1158/0008-5472.CAN-09-3556. View

2.
Haan C, Behrmann I . A cost effective non-commercial ECL-solution for Western blot detections yielding strong signals and low background. J Immunol Methods. 2006; 318(1-2):11-9. DOI: 10.1016/j.jim.2006.07.027. View

3.
Reitzer L, Wice B, Kennell D . Evidence that glutamine, not sugar, is the major energy source for cultured HeLa cells. J Biol Chem. 1979; 254(8):2669-76. View

4.
Xiao D, Ren P, Su H, Yue M, Xiu R, Hu Y . Myc promotes glutaminolysis in human neuroblastoma through direct activation of glutaminase 2. Oncotarget. 2015; 6(38):40655-66. PMC: 4747359. DOI: 10.18632/oncotarget.5821. View

5.
Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel P, Chesi M . Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res. 2004; 64(4):1546-58. DOI: 10.1158/0008-5472.can-03-2876. View